Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alessandro Allegra

Showing results (201-210 of 202) with videos related to

Pageof 21
Sort By:
You have reached the last page of results.This site can display upto 202 results.
Cancer|March 20, 2025
Dosing and clinical outcomes of ruxolitinib in patients with myelofibrosis in a real-world setting: Interim results of the Italian observational study (ROMEI)Massimo Breccia, Francesca Palandri, Maurizio Martelli, et al.
Hematological Oncology|March 25, 2026
Clinical Outcomes of Ruxolitinib Treatment in Patients With IPSS Intermediate-1-Risk Myelofibrosis: Interim Analysis From an Italian, Prospective Study (ROMEI)Paola Guglielmelli, Massimo Breccia, Francesco Mendicino, et al.
Pageof 21

Showing results (201-210 of 202) with videos related to

Sort By:
Pageof 21
You have reached the last page of results.This site can display upto 202 results.
Cancer|March 20, 2025
Dosing and clinical outcomes of ruxolitinib in patients with myelofibrosis in a real-world setting: Interim results of the Italian observational study (ROMEI)Massimo Breccia, Francesca Palandri, Maurizio Martelli, et al.
Hematological Oncology|March 25, 2026
Clinical Outcomes of Ruxolitinib Treatment in Patients With IPSS Intermediate-1-Risk Myelofibrosis: Interim Analysis From an Italian, Prospective Study (ROMEI)Paola Guglielmelli, Massimo Breccia, Francesco Mendicino, et al.
Pageof 21